PMID- 25637587
OWN - NLM
STAT- MEDLINE
DCOM- 20160120
LR  - 20191210
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 60
IP  - 10
DP  - 2015 May 15
TI  - Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported 
      to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
PG  - e58-65
LID - 10.1093/cid/civ061 [doi]
AB  - BACKGROUND: Limited data exist on the safety of the measles, mumps, and rubella 
      (MMR) vaccine in adults. We reviewed reports of adverse events (AEs) to the 
      Vaccine Adverse Event Reporting System (VAERS) to assess safety in this 
      previously understudied group. METHODS: VAERS is the national spontaneous vaccine 
      safety surveillance system coadministered by the Centers for Disease Control and 
      Prevention and the US Food and Drug Administration. We searched the VAERS 
      database for US reports of adults aged >/=19 years who received the MMR vaccine 
      from 1 January 2003 to 31 July 2013. We clinically reviewed reports and available 
      medical records for serious AEs, pregnancy reports, and reports for selected 
      prespecified outcomes. RESULTS: During this period, VAERS received 3175 US 
      reports after MMR vaccine in adults. Of these, 168 (5%) were classified as 
      serious, including 7 reports of death. Females accounted for 77% of reports. The 
      most common signs and symptoms for all reports were pyrexia (19%), rash (17%), 
      pain (13%), and arthralgia (13%). We did not detect any new safety findings in 
      empirical Bayesian data mining. We identified 131 reports of MMR vaccine 
      administered to a pregnant woman; the majority of these vaccinations were in the 
      first trimester and in 83 (62%), no AE was reported. CONCLUSIONS: In our review 
      of VAERS data, we did not detect any new or unexpected safety concerns for MMR 
      vaccination in adults. We identified reports of pregnant women exposed to MMR, 
      which is a group in whom the vaccine is contraindicated, suggesting the need for 
      continued provider education on vaccine recommendations and screening.
CI  - (c) The Author 2015. Published by Oxford University Press on behalf of the 
      Infectious Diseases Society of America. All rights reserved. For Permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Sukumaran, Lakshmi
AU  - Sukumaran L
AD  - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for 
      Disease Control and Prevention Emory University School of Medicine, Atlanta, 
      Georgia.
FAU - McNeil, Michael M
AU  - McNeil MM
AD  - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for 
      Disease Control and Prevention.
FAU - Moro, Pedro L
AU  - Moro PL
AD  - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for 
      Disease Control and Prevention.
FAU - Lewis, Paige W
AU  - Lewis PW
AD  - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for 
      Disease Control and Prevention.
FAU - Winiecki, Scott K
AU  - Winiecki SK
AD  - Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and 
      Research, US Food and Drug Administration, Silver Spring, Maryland.
FAU - Shimabukuro, Tom T
AU  - Shimabukuro TT
AD  - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for 
      Disease Control and Prevention.
LA  - eng
GR  - T32 AI074492/AI/NIAID NIH HHS/United States
GR  - T32AI074492/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150130
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Measles-Mumps-Rubella Vaccine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthralgia/chemically induced/epidemiology
MH  - Centers for Disease Control and Prevention, U.S.
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/*pathology
MH  - Exanthema/chemically induced/epidemiology
MH  - Female
MH  - Fever/chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Measles-Mumps-Rubella Vaccine/administration & dosage/*adverse effects
MH  - Middle Aged
MH  - Pain/chemically induced/epidemiology
MH  - Pregnancy
MH  - United States/epidemiology
MH  - Young Adult
PMC - PMC4447805
OTO - NOTNLM
OT  - MMR vaccine
OT  - Vaccine Adverse Event Reporting System (VAERS)
OT  - measles
OT  - mumps
OT  - rubella
EDAT- 2015/02/01 06:00
MHDA- 2016/01/21 06:00
PMCR- 2016/05/15
CRDT- 2015/02/01 06:00
PHST- 2014/11/07 00:00 [received]
PHST- 2015/01/21 00:00 [accepted]
PHST- 2015/02/01 06:00 [entrez]
PHST- 2015/02/01 06:00 [pubmed]
PHST- 2016/01/21 06:00 [medline]
PHST- 2016/05/15 00:00 [pmc-release]
AID - civ061 [pii]
AID - 10.1093/cid/civ061 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2015 May 15;60(10):e58-65. doi: 10.1093/cid/civ061. Epub 2015 
      Jan 30.